Morinda Officinalis Oligosaccharides Reduce Depression-Like Behaviors After Stroke Along with Higher Gut Bacteria Diversity, Increased Butyrate, and Lower Brain Inflammation Gene Activity

Morinda officinalis oligosaccharides (MOO), a clinically approved antidepressant in China, may interact with the microbiota-gut-brain axis in the context of post-stroke depression.

• Post-stroke depression (PSD) is a common complication following cerebral ischemia.
• Mechanism-based therapies for PSD are currently lacking.
• The microbiota-gut-brain axis is implicated in the development of PSD.
• MOO has poor oral absorption, suggesting a potential gut-dependent mechanism in its effects.
• Understanding the molecular pathways involved in PSD is essential for developing effective treatments.

Simplified